ReviewCureus2025
The Future of mRNA Vaccines: Potential Beyond COVID-19.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- mRNA Therapeutics Beyond Infectious Diseases: Expanding Therapeutic Applications and Future Perspectives.Immunity, inflammation and disease · 2026Review
- Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics.Current issues in molecular biology · 2026Review
- RepurNet: A network medicine framework for systematic drug repurposing and disease vulnerability discovery.iScience · 2026Article
- mRNA vaccines for viral diseases: mechanism, advances, and future perspective.Molecular biology reports · 2026Review
- NNature · 2026Article
- Ambient-Stable mRNA Medicines: Emerging Paradigms in Dry and Solid-State Formulation.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, mRNA therapeutics have emerged as a promising platform in treating a wide range of diseases, including cancers, infections, genetic disorders, and autoimmune diseases. This review focuses on the clinical impact of mRNA-based treatments and their transformative potential in modern medicine. mRNA therapeutics utilize the host's cellular machinery to produce target proteins, enabling highly specific and customizable treatments. In the case of cancer, mRNA vaccines to stimulate immune responses against such tumor-specific antigens are being developed in a personalized manner. Infectious diseases are also an indication for which mRNA vaccines have shown a significant effect on preventing viral infection, as the global success of mRNA COVID vaccines demonstrates. Among genetic disorders, mRNA therapy presents a new way to restore defective proteins and reverse the underlying pattern of genetic defects. Furthermore, mRNA treatment of autoimmune diseases aims to generate immune tolerance and avoid traditional immunosuppressive therapy. Advances are being driven by the discovery of new technologies to stabilize, deliver, and modulate the immune system around mRNAs. Recent advances in delivery systems and RNA stabilization have further expanded the potential of mRNA vaccines for viral diseases. mRNA therapeutics have the advantage of being rapidly developed and adaptable to a wide range. Research on further improvement of the delivery mechanisms and long-term safety will be necessary for extending the clinical applications of mRNA therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.